<< Full experiment listing


DataSet Summary

  • HostingRepository: PRIDE
  • AnnounceDate: 2018-05-16
  • AnnouncementXML: Submission_2018-05-16_02:04:49.xml
  • DigitalObjectIdentifier:
  • ReviewLevel: Peer-reviewed dataset
  • DatasetOrigin: Original data
  • RepositorySupport: Unsupported dataset by repository
  • PrimarySubmitter: Zhen Li
  • Title: CDK4/6 inhibitor resistance in prostate cancer
  • Description: CDK4/6 kinase inhibitors have shown great promise in clinical trials in various cancer types and have recently entered clinical trial for advanced prostate cancer. Although patients are expected to respond well to this class of drugs, development of resistance in some patients is anticipated. To pre-empt this and study how prostate cancer may evade CDK4/6 inhibition, new resistance models were generated from LNCaP and LAPC4 prostate cancer cells cells by prolonged culturing in presence of 0.5uM palbociclib. A shotgun phosphoproteomics approach was utilized and integrated with RNA sequencing data to unravel the molecular underpinnings of acquired resistance to palbociclib and resultant broad CDK4/6 inhibitor resistance.
  • SpeciesList: scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
  • ModificationList: phosphorylated residue
  • Instrument: Q Exactive HF

Dataset History

VersionDatetimeStatusChangeLog Entry
02017-05-22 06:08:19ID requested
12018-05-16 02:04:50announced

Publication List

  1. de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, Li Z, Cheng LC, Yoshida A, Courtney SM, Hazard ES, Hardiman G, Hussain MH, Diehl JA, Drake JM, Kelly WK, Knudsen KE, MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clin Cancer Res, 24(17):4201-4214(2018) [pubmed]

Keyword List

  1. curator keyword: Biomedical
  2. submitter keyword: Prostate cancer, CDK4/6, palbociclib, ribociclib, LNCaP, LAPC4

Contact List

    Justin M. Drake
    • contact affiliation: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA Graduate Program in Cellular and Molecular Pharmacology, Graduate School of Biomedical Sciences, Rutgers
    • contact email: jd1135@cinj.rutgers.edu
    • lab head:
    Zhen Li
    • contact affiliation: Rutgers Cancer Institute of New Jersey
    • contact email: zhen.li2000@rutgers.edu
    • dataset submitter:

Full Dataset Link List

  1. Dataset FTP location
  2. PRIDE project URI
Repository Record List
Subscribe to receive all new ProteomeXchange announcements!
If you have a question or comment about ProteomeXchange, please contact us!